New interactions reported for Strattera

The Summary of Product Characteristics for the ADHD treatment Strattera (atomoxetine) has been updated to warn of the possible risk of QT prolongation if the drug is used with other drugs that prolong the QT interval, cause electrolyte disturbances or inhibit CYP2D6.

Also, because of the risk of seizures, caution should be exercised with the concomitant use of drugs known to lower the seizure threshold.

Further information: Lilly, Lilly House, Priestley Road, Basingstoke, Hants RG24 9NL. Tel: (01256) 315000.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases